RxDoctor Payments Data

Samantha Dial, MD

Clinical Neurophysiology · Biddeford, MENPI 1669767562

Payments from drug & device makers

$5,471in general payments, 2019–2025

Across 409 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$790
  • Novartis$573
  • Biohaven Pharmaceutical Holding Company Ltd.$359
  • Lundbeck LLC$252
  • Avanir Pharmaceuticals, Inc.$235
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$5,471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical neurophysiology providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$224,933
Medicare patients
326
Services billed
24,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$342,737
Nurtec OdtRimegepant Sulfate17$25,434
Lacosamide81$17,057
RytaryCarbidopa/Levodopa11$14,448
Emgality PenGalcanezumab-Gnlm12$11,863
UbrelvyUbrogepant12$11,663
Pyridostigmine Bromide51$4,998
Topiramate ErTopiramate11$4,181
Mycophenolate Mofetil27$3,669
Carbidopa-LevodopaCarbidopa/Levodopa102$2,806
Gabapentin203$2,634
Pregabalin46$2,037
AmantadineAmantadine Hcl60$1,878
Phenobarbital52$865
Levetiracetam45$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$790$25,43417 claims
AbbVieUbrelvy$1,902$11,66312 claims
Upsher-smith Laboratories LLCTopiramate$23$20222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Maineon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →